Tafasitamab plus lenalidomide in refractory/relapsed primary cutaneous diffuse large B-cell lymphoma (ADO 2026) - Sep 7, 2026 - Abstract #FV 44; Pres time: Sep 12, 2026; 10:15 AM - 10:22 AM; Location: Telemann Hall; No abstract available
B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma
|
|
Prof. Marion Wobser; Prof. Dr. Andreas Rosenwald; Dr. Katja Maurus; Dr. Florian Eisele; Prof. Max Topp; Dr. Johannes Düll
|